Molecular Classification of Endometrial Cancer and the 2023 FIGO Staging: Exploring the Challenges and Opportunities for Pathologists

This commentary explores the complexities of FIGO 2023 staging system and inclusion The Cancer Genome Atlas’s (TCGA) molecular classification in management endometrial cancer. It highlights importance histology as a prognostic tool, while scrutinizing merits demerits its application to aggressive cancers. review sheds light on recent introductions lymphovascular space invasion (LVSI) lymph node metastasis size cancer staging. outlines difficulties differentiating between synchronous metastatic ovarian cancers, underlining their implications treatment strategies. Furthermore, discusses integration classifications within framework, emphasizing pivotal yet challenging implementation pathogenic POLE mutation test. concludes by reaffirming vital role pathologists executing system.